newsfilter
← Latest News
GlobeNewswire·

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease Two poster presentations will highlight preclinical research supporting the